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Urotensin II (UII) is a vasoactive peptide thatwas ﬁrst discovered in the teleost ﬁsh, and later
in mammals and humans. UII binds to the G protein coupled receptor GPR14 (now known
as UT). UII mediates important physiological and pathological actions by interacting with its
receptor.The metabolic syndrome (MetS) is described as cluster of factors such as obesity,
dyslipidemia, hypertension, and insulin resistance (IR), further leading to development of
type 2 diabetes mellitus and cardiovascular diseases. UII levels are upregulated in patients
with the MetS. Evidence directly implicating UII in every risk factor of the MetS has been
accumulated. The mechanism that links the different aspects of the MetS relies primarily
on IR and inﬂammation. By directly modulating both of these factors, UII is thought to play
a central role in the pathogenesis of the MetS. Moreover, UII also plays an important role
in hypertension and hyperlipidemia thereby contributing to cardiovascular complications
associated with the MetS.
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UROTENSIN II
The peptide Urotensin II (UII) was ﬁrst identiﬁed in the teleost
ﬁsh Gillichthys mirabilis (Pearson et al., 1980). Homologs of this
peptide were subsequently found in mammals and humans (Pear-
son et al., 1980; Conlon et al., 1996; Ames et al., 1999; Coulouarn
et al., 1999). Although the amino acid sequence of these homologs
changes depending on the species, a cyclic sequence of six amino
acids is conserved (Cys-Phe-Trp-Lys-Tyr-Cys). It is believed that
this sequence is responsible for the biological activity of the pep-
tide (Conlon et al., 1990). UII acts as a vasoactive peptide by
binding to the G protein coupled receptor GPR14, better known
as UT (Ames et al., 1999; Liu et al., 1999). A recent study has
shown that UII vasoconstrictive effects are mediated by calcium
inﬂux via STIM1 and Orai-1 (Domínguez-Rodríguez et al., 2012).
Human UII (hUII) and its receptor have been found in cardiac
and vascular tissues, spinal cord, central nervous system, kid-
ney, liver, and pancreas (Maguire et al., 2000; Matsushita et al.,
2001). UII is also present in the blood plasma in picomolar con-
centrations (Matsushita et al., 2001). However, it tends to act
mainly in an autocrine and paracrine fashion rather than as
a hormone (Yoshimoto et al., 2004). Even though the relation
between UII and its receptor was made in 1999, the physio-
logical and pathological roles of UII are only beginning to be
unraveled. In a healthy state, the binding of UII with UT is
known to play an important role in the control of vascular tone,
blood pressure, and insulin release (Douglas and Ohlstein, 2000;
Douglas et al., 2000; Loirand et al., 2008). UII has been identi-
ﬁed as the most potent vasoactive peptide known to date, being
more potent vasoconstrictor than endothelin-1 and angiotensin-
II (Ames et al., 1999; Douglas and Ohlstein, 2000; Maguire et al.,
2000). UII also controls the function of vascular smooth-muscle
cells (VSMCs) through the release of endothelial-cell-derived
vasodilators such as nitric oxide (Gibson, 1987; Gardiner et al.,
2001; Stirrat et al., 2001). The role of UII in pathological states
is still debated. Many studies have shown increased levels of UII
and its receptor in diverse cardiovascular and metabolic diseases
such as type 2 diabetes mellitus, renal dysfunction, atheroscle-
rosis, systematic and essential hypertension, obesity, congestive
heart failure, myocardial infarction, cardiac ﬁbrosis, hypertro-
phy, and remodeling (Reviewed in Hassan et al., 2003; Ross
et al., 2010; Gruson et al., 2012). The elevated levels of UII in
disease states suggest that UII is expressed either as a protec-
tive response to pathologies or as a pathological agent. Some
studies claim that temporary elevation of UII levels may lower
cardiovascular disease risk factors in end-stage renal disease (Mal-
lamaci et al., 2005; Zoccali et al., 2006), myocardial infarction
(Babin´ska et al., 2012) and restore endothelial function (Zoc-
cali and Mallamaci, 2008). On the other hand, other studies
have demonstrated that UII acts as a pathological agent inducing
cardiac hypertrophy in synergy with angiotensin II by phospho-
rylation of the Akt kinase (Chanalaris et al., 2005; Gruson et al.,
2010b, 2012).
METABOLIC SYNDROME
As mentioned above, the metabolic syndrome (MetS) consists of
a set of risk factors, such as obesity, hyperlipidemia, hypertension,
hyperglycemia, and insulin resistance (IR), leading to the devel-
opment of type 2 diabetes, cardiovascular diseases, non-alcoholic
fatty liver disease, and renal impairment (Grundy, 1999; Cho,
2011). The relation between these risk factors and complications
seems to be mostly attributed to IR (Eckel et al., 2010), which is
why the syndrome was ﬁrst deﬁned as an IR syndrome (Reaven,
1988). Since then, the National Cholesterol Education Program
(NCEP)-Adult Treatment Panel III, the World Health Organiza-
tion (WHO) and the International Diabetes Federation (IDF) set
up some criteria for the clinical deﬁnition of MetS.
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A recent study using data from the 2003–2006 National Health
and Nutrition Examination Survey and the NCEP/IDF MetS cri-
teria, revealed that the prevalence of MetS was 34.3% among
all adults in the US (Ford et al., 2010). However, high preva-
lence of MetS is not only restricted to the Western world. MetS
seems to be highly prevalent in sub-Saharan Africa, Middle-East,
South America, and South Asian Countries (Misra and Khurana,
2008). Central obesity is considered the main precursor to MetS
(Cameron et al., 2008). According to the WHO, the global obese
population increased from 200 million in 1995 to 300 million in
2000. The WHO has also determined that the obesity epidemic is
also spreading in developing countries with over 115 million peo-
ple suffering from obesity-related illnesses (Misra and Khurana,
2008; WHO, 2008). Popkin and Doak (1998) have also reported
increasing obesity prevalence in the United States, Latin America,
Europe, andAsia,which conﬁrms theworldwide epidemic propor-
tions of obesity and overweight. In addition, the Aerobic Center
Longitudinal Study, which included 33,230 cancer-free men fol-
lowed for 14 years, showed 56% enhanced risk of cancer mortality
for men affected by MetS (Jaggers et al., 2009). The direct implica-
tion of the syndrome in CVD, type 2 diabetes, non-alcoholic fatty
liver, and cancer, as well as an increasing prevalence of obesity and
decreased physical inactivity in Western societies makes the MetS
a major health preoccupation (NCEP, 2002)
Recent researches have shown thatUII has an impact on the risk
factors as well as the overall pathogenesis of the MetS (Ong et al.,
2008). A study using the American Heart Association/National
Heart, Lung, and Blood Institute criteria for MetS revealed that
MetS patients show higher plasma levels of UII (Gruson et al.,
2010a). Our group also demonstrated an increase in UII plasma
levels in mice when all risk factors of MetS are present (You et al.,
2012). Moreover, we recently found that UII gene deletion in mice
(UIIKO) signiﬁcantly decreased body mass, visceral fat, blood
pressure, and increased insulin and glucose tolerance when com-
pared to wild-type mice (You et al., 2012). Even though there is a
clear association between MetS and UII, it is still unclear whether
the peptide plays a role in the initiation of the disease, or if the
elevated plasma levels of UII are a result of the syndrome. This
review aims to give a closer look at the implication of UII in the
risk factors and pathways involved in the development of theMetS.
INSULIN RESISTANCE (IR)
Insulin plays a major role in glucose and lipid metabolism such
as adipose tissue triglyceride lipolysis, lipoprotein lipase activity,
muscle and adipose tissue glucose absorption, muscle and liver
glycogen synthesis, and endogenous glucose production (Cornier
et al., 2008). When cells react poorly to an insulin stimulus, they
are deﬁned as IR. The latter is known to be the link between
the individual components of MetS (Eckel et al., 2010). For
instance, it seems that IR correlates positively with atherosclero-
sis (Fernández-Real and Ricart, 2003) and coronary artery disease
(CAD; Juhan-Vague et al., 1991), and also an indirect cause of
hyperinsulinemia (Reaven, 2003), dyslipidemia, hyperglycemia,
and hypertension (Sowers, 2004) through an increase in free
fatty acid (FFA) synthesis in adipose tissue (Boden and Shulman,
2002) and a chronic inﬂammatory response (Fernández-Real and
Ricart, 2003).
The IR Atherosclerosis Study (IRAS) and the Atherosclero-
sis Risk in Communities Study showed that insulin sensitivity
(measured with an intravenous glucose tolerance test) correlates
negatively with intimal-medial thickness of the carotid artery
(Howard et al., 1996). Subsequent studies also found a signiﬁ-
cant correlation between carotid intimal-media thickening and IR
and hyperinsulinemia (Golden et al., 2002; Zavaroni et al., 2006).
Intimal-media thickness has been shown to be a signiﬁcant pre-
dictor of myocardial infarction and coronary death (Hodis et al.,
1998). As a result, IR is a major risk factor in developing cardiovas-
cular complications. Indeed, IR has been associated with increased
plasma levels of plasminogen activator inhibitor 1 (PAI-1; Juhan-
Vague et al., 1991). Increased levels of PAI-1 are known to impair
ﬁbrinolysis, which leads to progression of coronary atheroscle-
rosis in glucose intolerant patients (Bavenholm et al., 1998) and
increased risk of myocardial reinfarctionwithin 3 years in less than
45-year-old men (Hamsten et al., 1985, 1987; Gram et al., 1987;
Juhan-Vague et al., 1991) as well as increased risk of CAD (Juhan-
Vague et al., 1991). UII is known to increase expression of PAI-1 in
vascular SMC (Djordjevic et al., 2005), hence UII may contribute
to atherosclerosis through PAI-1 inhibition of ﬁbrinolysis.
Free fatty acids play an important role in MetS by having
direct effects on dyslipidemia, hypertension (Fagot-Campagna
et al., 1998), IR (Boden, 1997), and pancreatic β-cell dysfunc-
tion (Sako and Grill, 1990; Unger, 1995; McGarry and Dobbins,
1999; Boden and Shulman, 2002). Impaired insulin action in adi-
pose tissue tends to increase FFAs concentrations in the plasma
by reducing the insulin inhibition of adipose tissue triglyceride
lipolysis (Randle et al., 1963; Randle, 1998; Kahn and Flier, 2000;
Cornier et al., 2008). On the other hand, FFAs induce IR in skele-
tal muscles (DeFronzo et al., 1985) and liver by inhibiting insulin
suppression of glycogenolysis (Boden et al., 2002), which results in
a vicious cycle increasing IR, FFA levels, and promotion of hyper-
glycemia. Furthermore, higher plasma glucose and FFA levels tend
to increase insulin secretion in the pancreas (Boden and Shulman,
2002), thus leading to hyperinsulinemia. Such high plasma insulin
levels promote hypertension (Welborn et al., 1966; Reaven, 2003),
which is another risk factor of MetS. An increase in FFA levels
also predicts development of type 2 diabetes (Paolisso et al., 1995;
Charles et al., 1997). In the liver, higher FFA levels increase low
density lipoprotein (LDL) and triglyceride production, while low-
ering high density lipoprotein (HDL) production (Brinton et al.,
1991; Muramaki et al., 1995).
The direct effects of UII on lipid mobilization and FFA release
are somewhat contradictory. In the coho salmon, administration
of UII stimulated the activity of triacylglycerol lipase and the
release of FFAs in the liver (Sheridan and Bern, 1986; Sheridan
et al., 1987). On the contrary, UII injection in dogﬁsh showed
no signiﬁcant increase in FFA release or plasma triglyceride con-
centrations (Conlon et al., 1994). We recently found that UII gene
deletion in mice fed high fat diet signiﬁcantly reduced serum levels
of FFAs in comparison with wild-type (You et al., 2012). In light of
our own ﬁndings and those of others linking UII to IR and glucose
metabolism (Silvestre et al., 2001, 2004; Ong et al., 2006; You et al.,
2012), we suggest that UII may mediate lipid mobilization and
FFA indirectly through IR. However, the direct inﬂuence of UII in
lipid metabolism still requires further research.
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The role of UII in the MetS seems to be closely related to
insulin activity and the overall glucose metabolism in the pan-
creas (Figure 1). In fact, UII and UT are both expressed in rat
pancreatic islets, where their interaction seems to inhibit glucose-
mediated insulin release (Silvestre et al., 2001, 2004). Also, when
high concentrations of UII are administrated to the rat pancreas,
glucose and arginine induced insulin response are blocked (Sil-
vestre et al., 2001, 2004). Some UII and UT gene haplotypes are
known to be associated with IR (Ong et al., 2006), impaired glu-
cose tolerance (Ong et al., 2006), β-cell pancreatic function, and
type 2 diabetes (Sun et al., 2002; Zhu et al., 2002;Wenyi et al., 2003;
Suzuki et al., 2004; Tan et al., 2006; Sáez et al., 2011). UII upreg-
ulation in plasma and skeletal muscle in type 2 diabetes mellitus
is coherent with this association (Totsune et al., 2003; Wang et al.,
2009). In addition,UII increases glucose-6-phosphatase activity in
salmon liver, which tends to reduce glycogen content and increase
glucose levels, leading to hyperglycemia. Our recent study has
demonstrated that UII gene knockout in mice reduced serum glu-
cose and insulin, and increased glucose and insulin tolerance in
comparison with wild-type mice (You et al., 2012).
INFLAMMATORY RESPONSE IN THE MetS
It is well known that IR and MetS are both associated with an
inﬂammatory response (Sutherland et al., 2004). The relation-
ship between IR and inﬂammation seems to be bidirectional; IR
promotes an inﬂammatory response and vice versa (Fernández-
Real and Ricart, 2003), resulting in a vicious circle increasing
risk of MetS incidence. An acute-phase inﬂammatory response
is not only linked with IR (Fernández-Real et al., 2001; Festa
et al., 2002; Grimble, 2002; Leinonen et al., 2003), but also with
type 2 diabetes (McMillan, 1989; Arnalich et al., 2000; Festa et al.,
2002; Leinonen et al., 2003), obesity (Laimer et al., 2002; Leinonen
et al., 2003), and the overall MetS (Chan et al., 2002; Das, 2002).
The activity of inﬂammatory markers such as C-reactive pro-
tein, tumor necrosis factor-alpha (TNF-α), Interleukin-18 (IL-18)
and PAI-1 increases as the presence of MetS risk factors increase
(Cornier et al., 2008).
Tumor necrosis factor-alpha prevents the action of insulin in
cultured cells and in animal models (Hotamisligil et al., 1993,
1994, 1996) by inducing serine phosphorylation of the insulin
receptor substrate-1, which reduces the tyrosine kinase activity
FIGURE 1 | Summary of the role of Urotensin II (UII) on insulin activity
and glucose metabolism associated with the metabolic syndrome. UII
expressed in the pancreas acts directly to impair glucose tolerance, reduce
glucose-mediated insulin release, impair pancreatic β-cell function, and block
insulin response resulting in IR and increased risk of type 2 diabetes and
cardiovascular diseases.
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of the insulin receptor (Hotamisligil et al., 1996), resulting in IR.
Furthermore, TNF-α stimulates the production of endothelin-1
(Kahaleh and Fan, 1997) and angiotensin (Brasier et al., 1996) in
vitro, which are directly involved in vasoconstriction and thus may
lead to increased hypertension. Indeed, there is a positive corre-
lation between TNF-α, systolic blood pressure, and IR (Dörffel
et al., 1999). TNF-α also stimulates VLDL production (Grunfeld
and Feingold, 1992) and decreases HDL cholesterol (Jovinge et al.,
1998). Dyslipidemia in mice is signiﬁcantly related to increased
TNF-α levels (Fleet et al., 1992).
Elevated levels of the inﬂammatory cytokine IL-6 are asso-
ciated with obesity, IR (Fried et al., 1998; Bastard et al., 2000;
Fernández-Real et al., 2001; Kern et al., 2001; Bastard et al., 2002),
and type 2 diabetes (Pradhan et al., 2001; Vozarova et al., 2003).
IL-6 also plays a role in the pathology of dyslipidemia by decreas-
ing LPL activity in adipocytes (Greenberg et al., 1992) which
increases hepatic triglyceride levels (Nonogaki et al., 1995). In
man, IL-6 correlates with increased FFA (Stouthard et al., 1995),
fasting triglycerides, and VLDL (Fernández-Real et al., 2000), and
decreased HDL cholesterol (Zuliani et al., 2007). This cytokine
may also have an impact on hypertension by stimulating the
sympathetic and central nervous system (Besedovsky and Del
Rey, 1996; Papanicolaou et al., 1996), and angiotensin expression
(Takano et al., 2000).
The central role of the inﬂammatory response in MetS is
also related to UII and UT expression (Figure 2). Inﬂamma-
tory cells including lymphocytes, macrophages, monocytes, and
foam cells express UII and UT mRNA (Bousette et al., 2004).
Lymphocytes are by far the largest producers of UII, whereas
monocytes and macrophages produce the highest levels of UT.
Moreover, inﬂammatory markers such as TNF-α, lipopolysaccha-
ride, and interferon-γ are all known to induce UT expression in
vitro (Segain et al., 2007). These ﬁndings suggest that an inﬂam-
matory response to MetS and its components may increase UII
levels by increasing inﬂammatory cells production of the pep-
tide. On the other hand, UII is known to contribute to the
inﬂammatory response by inducing the release of inﬂammatory
cytokines like IL-6 in cardiomyocytes (Sano et al., 2000; Tzani-
dis et al., 2003; Johns et al., 2004; Russell and Molenaar, 2004).
UII mediates aortic inﬂammation by stimulating the release of
leukotriene C (LTC4), a lipid inﬂammatory mediator, from aor-
tic adventitial ﬁbroblasts through 5-lipoxygenase pathway (Dong
FIGURE 2 | Summary of the role of Urotensin II (UII) on the inflammatory
response associated with the metabolic syndrome. Inﬂammatory
cytokines increase UII and UT expression and vice-versa, resulting in a
positive feedback. The ensuing chronic inﬂammation is directly involved in the
development of obesity, insulin resistance, dyslipidemia, hypertension, and
atherosclerosis.
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et al., 2012). LTC4 plays a key role in the pathogenesis of atheroscle-
rosis as a chemoattractant and activator for monocytes in the
vascular endothelium. It is also known to initiate contraction
of smooth muscle cells in the adjacent medial tissues of the
vasculature (Dong et al., 2012). In addition, we have recently
shown that UII gene deletion in mice fed a high fat diet reduces
the serum levels of inﬂammatory cytokines including monocyte
chemoattractant protein-1, monokine induced by γ-interferon,
and keratinocyte chemoattractant when compared to wild-type
mice (You et al., 2012).
UII, HYPERTENSION, AND CARDIOVASCULAR DISEASES
The MetS is identiﬁed as a clustering of risk factors that perpet-
uate cardiovascular diseases. Since UII has been shown to play a
role in the pathogenesis of atherosclerosis (Maguire et al., 2004;
Hassan et al., 2005; Papadopoulos et al., 2009), congestive heart
failure (Hassan et al., 2003), myocardial ischemia (Zhang et al.,
2002; Zhou et al., 2003), ventricular hypertrophy, and ﬁbrosis
(Sano et al., 2000; Tzanidis et al., 2003; Johns et al., 2004; Rus-
sell and Molenaar, 2004), it is therefore reasonable to suggest that
induction of UII in the MetS may contribute to the cardiovascular
abnormalities associated with this syndrome.
Atherosclerosis is the main cause of morbidity and mortality in
cardiovascular diseases and cause of death in the Western world
(Libby et al., 2009). Atherosclerosis is known to induce UT and
UII overexpression in mice aortic tissues (Douglas et al., 2002;
Bousette et al., 2004; Wang et al., 2006; Libby et al., 2009). In mice
overexpressing UT receptor (UT+), aortic atherosclerosis lesion
formation is signiﬁcantly increased (Papadopoulos et al., 2009),
whereas lesion formation is decreased in UIIKO mice with an
atherosclerotic background (APOE;You et al., 2012). UII is known
to promote vascular remodeling by mediating VSMC prolifera-
tion and migration inside the intima, a process directly involved
in atherogenesis (Sauzeau et al., 2001; Watanabe et al., 2001a,b;
Tamura et al., 2003; Albertin et al., 2009; Iglewski and Grant,
2010). It has been suggested that vascular endothelial growth
factor (VEGF), a major angiogenic protein, could be respon-
sible for UII-mediated vascular remodeling. Even though UII
does not affect VEGF expression in human endothelium (Albertin
et al., 2009), recent evidence has shown that UII induces secre-
tion of VEGF in the adventitia in synergy with angiotensin II
(Song et al., 2012). VEGF stimulates proliferation of endothe-
lial and smooth muscles cells while also stimulating proliferation
and migration of adventitial ﬁbroblasts in the intima (Sartore
et al., 2001; Stenmark et al., 2006; Zhang et al., 2008). In addition,
UII contributes to the inﬂammatory response in atherosclero-
sis by acting as a chemoattractant for monocytes (Segain et al.,
2007) and increasing IL-6 expression in cardiomyocytes (Sano
et al., 2000; Tzanidis et al., 2003; Johns et al., 2004; Russell and
Molenaar, 2004). UII interacts with UT receptors on the sur-
face of macrophages to promote expression of ACAT-1 (Watanabe
et al., 2005). ACAT-1 is known to accelerate foam cells formation,
which has a major impact on atherosclerotic lesion development
(Watanabe et al., 2005). Another main effect of UII on atheroscle-
rosis is the increased expression of NADPH oxidase, which is a
main source of reactive oxygen species (ROS; Djordjevic et al.,
2005; Tsoukas et al., 2011). ROS are central in the early initiation
of atherosclerosis by converting LDL into oxidized-LDL (Djord-
jevic et al., 2005). NADPH oxidase-derived superoxide inacti-
vates nitric oxide, resulting in impaired endothelial dependant
vasodilatation (Zou et al., 2004) and hypertension (Lassègue and
Clempus, 2003).
Urotensin II also contributes to essential (Matsushita et al.,
2001) and secondary (Heller et al., 2002) hypertension by inducing
vascular remodeling. Increased blood pressure in cats (Behm et al.,
2004), rats (Lin et al., 2003), and sheep (Watson et al., 2003) with
UII administration is coherent with these ﬁndings. In humans,
plasma UII correlates positively with systolic blood pressure, inde-
pendently of an atherosclerotic background (Cheung et al., 2004).
Indeed, the UII gene (UTS2) is associated with essential hyperten-
sion (Yi et al., 2006) and myocardial infarction (Nishihama et al.,
2007; Oguri et al., 2009). In a chronic heart failure or essential
hypertension state, UII loses its dilatory function (Lim et al., 2004;
Sondermeijer et al., 2005).
UII, OBESITY, AND HYPERLIPIDEMIA
Obesity seems to be a main cause of IR in both men and
women (Carey et al., 1996; Cornier et al., 2008; Stefan et al.,
2008). Moreover, it seems that physical activity and a diet rich
in monounsaturated or hydrogenated fat leads to an impairment
of insulin sensitivity (Mayer-Davis et al., 1998; Vessby et al., 2001;
Han et al., 2002). Obesity is also known as a chronic inﬂamma-
tory state; it induces release of proinﬂammatory cytokines and
adipokines (Yudkin et al., 1999; Festa et al., 2001; Engström et al.,
2003; Trayhurn and Wood, 2004). As a result, the pathologic role
of inﬂammation in IR and MetS may be enhanced by obesity.
However, some suggest that obesity may be, on the opposite, an
outcome of inﬂammation (Das, 2001). Obesity may contribute to
increase local IR in the adipocytes as well as in other tissue such
as the liver and skeletal muscles (Cornier et al., 2008; Gregor and
Hotamisligil, 2011).
Plasma UII correlates positively with body weight in humans
independently of atherosclerotic background (Cheung et al.,
2004). Adipokines (dipeptidyl peptidase-4, endocan, insulin-like
growth factor-binding proteins), known to play a role in diabetes
mellitus andobesity (Janke et al., 2006; Neumiller et al., 2010; Ruan
and Lai, 2010) were reduced in UII/ApoE double knockout mice
in comparison with ApoEKO (You et al., 2012). Reduction of body
mass, visceral fat, visceral adipocytes diameter, serumLDL, triglyc-
erides, as well as increase in HDL is also observed with UII gene
deletion in mice (You et al., 2012; Figure 3). A reduction in hep-
atic cholesterol esteriﬁcation is also observed in UIIKO mice (Kiss
et al., 2011). These results are attributed to a reduction in choles-
terol and apolipoprotein B production by hepatocytes (Kiss et al.,
2011). Furthermore, Jiang et al. (2008) found that the UII gene
(UTS2) regulates fat accumulation in humans.
CONCLUSION
The mechanism that links the various components of MetS relies
primarily on IR and inﬂammation (Sutherland et al., 2004; Eckel
et al., 2010). The ability of UII to modulate both of these factors
suggests an important role for the peptide in the pathogenesis of
the MetS. Other risk factors mediated by UII, such as obesity, may
tend to initiate the positive feedback cycle, which contributes to
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FIGURE 3 | Hematoxylin and eosin staining of visceral adipose tissue sections in wild-type mice (A) and UIIKO mice (B). Adipocytes of UIIKO mice
appear smaller than wild-type mice.
the development of MetS. In fact, genetic manipulation or the use
of UT receptor antagonists seems to have a positive effect on every
risk factor of the MetS (You et al., 2012). However, it is still unclear
whether UII is important in the initiation or only in the pro-
gression and further complications of the disease. The biological
activities of UII, and the recent reports of increased serum lev-
els of UII in patients with the MetS suggest that pharmacological
manipulation of the UII pathway as a possible future treatment of
the syndrome.
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